Arndt Justus Georg Schottelius
Director/Board Member chez GUBRA A/S
Fortune : 253 515 $ au 31/03/2024
Profil
Arndt Justus Georg Schottelius is currently the Chief Executive Officer at Maxion Therapeutics Ltd.
and an Independent Director at Gubra A.
Previously, he held positions such as Medical Director-Immunology Development at Genentech, Inc., Chief Development Officer at MorphoSys AG, Executive VP & Head-Research & Development at Kymab Ltd., and Chief Scientific Officer at Affimed NV from 2020 to 2024.
Dr. Schottelius obtained a doctorate degree from the University of Freiburg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AFFIMED N.V.
0,32% | 15/03/2023 | 47 833 ( 0,32% ) | 253 515 $ | 31/03/2024 |
Postes actifs de Arndt Justus Georg Schottelius
| Sociétés | Poste | Début |
|---|---|---|
| GUBRA A/S | Director/Board Member | 01/01/2022 |
Maxion Therapeutics Ltd.
 Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Chief Executive Officer | 01/03/2024 |
Anciens postes connus de Arndt Justus Georg Schottelius
| Sociétés | Poste | Fin |
|---|---|---|
| AFFIMED N.V. | Chief Tech/Sci/R&D Officer | 29/02/2024 |
| MORPHOSYS AG | Corporate Officer/Principal | 01/03/2017 |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | - |
Formation de Arndt Justus Georg Schottelius
| University of Freiburg | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AFFIMED N.V. | Health Technology |
| MORPHOSYS AG | Health Technology |
| GUBRA A/S | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Health Technology |
